Literature DB >> 9062371

The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients.

R Garcia-Morales1, M Carreno, J Mathew, K Zucker, R Cirocco, G Ciancio, G Burke, D Roth, D Temple, A Rosen, L Fuller, V Esquenazi, T Karatzas, C Ricordi, A Tzakis, J Miller.   

Abstract

40 recipients of first cadaver kidney transplants were given perioperative donor vertebral bone marrow infusions (DBMC), compared with 100 controls who did not receive donor bone marrow. The immunosuppressive regimen included OKT3, Tacrolimus, and steroid maintenance therapy, and, in some patients, newly introduced mycophenolate mofetil. This report describes the 24-mo actuarial follow-up and several immunological monitoring studies including sequential measurements of donor bone marrow lineage subset chimerism by the recently reported PCR-flow assay. This is a sensitive in situ PCR detection system for donor versus recipient histocompatibility genes as well as cell surface CD epitope markers using flow cytometry. The results indicate (a) the stabilization of the donor CD3+ and CD34+ cells in recipient peripheral blood at levels below 1% between 6 mo and 1 yr postoperatively, with a 10-fold higher level of donor cell chimerism of these lineages in recipient iliac crest marrow; (b) significantly lower levels of chimerism in peripheral blood up to 6 mo postoperatively in patients who had early acute (reversible) rejection episodes compared with those who did not; (c) a higher degree of chimerism seen in patients who were class II MHC HLA DR identical with their donors; (d) the identification of a high proportion of the donor bone marrow derived CD3 dimly staining subset of T cells (to which regulatory functions have been ascribed) in recipient peripheral blood and especially in recipient bone marrow; and (e) an unexpectedly increased susceptibility to clinically significant infections (primarily viral), and even death in the DBMC-infused group, compared with controls, but no graft losses because of rejection in the DBMC-infused group. Mixed lymphocyte culture assays showed a trend toward a greater number of nonspecifically low reactors in the DBMC group, as well as a greater number of nonspecifically high reactors in the controls (P = 0.058). The autologous mixed lymphocyte reaction also indicated a trend towards nonspecific immune activation in the DBMC group. Finally, anti-cytomegaloviral IgG antibody reactivity was significantly inhibited in the DBMC group 4-6 mo postoperatively (P = < 0.05). In the controls, there were no donor cell lineages detected by PCR-flow in the peripheral blood. These rather unexpected findings, indicating a more depressed cellular and humoral immune capacity in the DBMC cadaver kidney transplant recipients in this relatively early follow-up period, are discussed relevant to chimerism, MHC restriction, and suppressor activity brought about by specialized DBMC subsets, which still need to be defined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062371      PMCID: PMC507921          DOI: 10.1172/JCI119240

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

Review 2.  Mouse NK1.1+ T cells: a new family of T cells.

Authors:  A P Vicari; A Zlotnik
Journal:  Immunol Today       Date:  1996-02

3.  In vitro generation of human mixed lymphocyte culture suppressor cells. I. Cellular characterization and specificity.

Authors:  L Fuller; G Kyriakides; C Flaa; V Esquenazi; J Miller
Journal:  Transplantation       Date:  1980       Impact factor: 4.939

4.  Enrichment of murine bone marrow natural suppressor activity in the fraction of hematopoietic progenitors with interleukin 3 receptor-associated antigen.

Authors:  K Sugiura; S Ikehara; M Inaba; S Haraguchi; H Ogata; E E Sardiña; M Sugawara; Y Ohta; R A Good
Journal:  Exp Hematol       Date:  1992-02       Impact factor: 3.084

5.  IMMUNOLOGIC INCOMPETENCE OF IMMUNOLOGICALLY RUNTED ANIMALS.

Authors:  R M BLAESE; C MARTINEZ; R A GOOD
Journal:  J Exp Med       Date:  1964-02-01       Impact factor: 14.307

6.  Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation.

Authors:  P Fontes; A S Rao; A J Demetris; A Zeevi; M Trucco; P Carroll; W Rybka; W A Rudert; C Ricordi; F Dodson
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

7.  Kidney allograft tolerance in primates without chronic immunosuppression--the role of veto cells.

Authors:  J M Thomas; F M Carver; P R Cunningham; L C Olson; F T Thomas
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

8.  Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation.

Authors:  T E Starzl; A J Demetris; M Trucco; A Zeevi; H Ramos; P Terasaki; W A Rudert; M Kocova; C Ricordi; S Ildstad
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

9.  Effect of class II antigen matching on renal allograft survival in miniature swine.

Authors:  M D Pescovitz; J R Thistlethwaite; H Auchincloss; S T Ildstad; T G Sharp; R Terrill; D H Sachs
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection.

Authors:  C P Larsen; P J Morris; J M Austyn
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  13 in total

1.  Kidney transplantation with bone marrow augmentation: five-year outcomes.

Authors:  R Shapiro; A S Rao; R J Corry; M Valenti; A Zeevi; M L Jordan; V P Scantlebury; C A Vivas; A Jain; J McCauley; P Randhawa; E A Gray; I Dvorchik; J McMichael; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Four-color flow cytometric analysis of peripheral blood donor cell chimerism.

Authors:  Diana Metes; Alison Logar; William A Rudert; Adriana Zeevi; Jennifer Woodward; Anthony J Demetris; Kareem Abu-Elmagd; Bijan Eghtesad; Ron Shapiro; John J Fung; Massimo Trucco; Thomas E Starzl; Noriko Murase
Journal:  Hum Immunol       Date:  2003-08       Impact factor: 2.850

Review 3.  Bone marrow augmentation in renal transplant recipients.

Authors:  R Shapiro; T E Starzl
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

4.  Effects of donor bone marrow infusion in clinical lung transplantation.

Authors:  S M Pham; A S Rao; A Zeevi; K R McCurry; R J Keenan; J D Vega; R L Kormos; B G Hattler; J J Fung; T E Starzl; B P Griffith
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

5.  A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results.

Authors:  S M Pham; A S Rao; A Zeevi; R L Kormos; K R McCurry; B G Hattler; J J Fung; T E Starzl; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2000-04       Impact factor: 5.209

Review 6.  Microchimerism in promoting graft acceptance in clinical transplantation.

Authors:  James M Mathew; Joseph R Leventhal; Joshua Miller
Journal:  Curr Opin Organ Transplant       Date:  2011-08       Impact factor: 2.640

7.  Donor-derived peripheral mononuclear cell DNA is associated with stable kidney allograft function: a randomized controlled trial.

Authors:  Ghasem Solgi; Joannis Mytilineos; Vijayakrishna Gadi; Biswajit Paul; Gholamreza Pourmand; Abdolrasoul Mehrsai; Behrouz Nikbin; Ali Akbar Amirzargar
Journal:  Chimerism       Date:  2011 Oct-Dec

8.  A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab.

Authors:  Gaetano Ciancio; Junichiro Sageshima; Edip Akpinar; Jeffrey J Gaynor; Linda Chen; Alberto Zarak; Lois Hanson; Lissett Tueros; Giselle Guerra; Adela Mattiazzi; Warren Kupin; David Roth; Camillo Ricordi; George W Burke
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

9.  Transplantation of the spleen: effect of splenic allograft in human multivisceral transplantation.

Authors:  Tomoaki Kato; Andreas G Tzakis; Gennaro Selvaggi; Jeffrey J Gaynor; Hidenori Takahashi; James Mathew; Rolando Garcia-Morales; Erick Hernandez; Andre David; Seigo Nishida; David Levi; Jang Moon; Eddie Island; Gary Kleiner; Phillip Ruiz
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

10.  Simultaneous, Single-Cell Measurement of Messenger RNA, Cell Surface Proteins, and Intracellular Proteins.

Authors:  Kah Teong Soh; Joseph D Tario; Sean Colligan; Orla Maguire; Dalin Pan; Hans Minderman; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.